Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2022

Open Access 01-12-2022 | Review

Sclerostin is a promising therapeutic target for oral inflammation and regenerative dentistry

Authors: Chufang Liao, Shanshan Liang, Yining Wang, Ting Zhong, Xiangning Liu

Published in: Journal of Translational Medicine | Issue 1/2022

Login to get access

Abstract

Sclerostin is the protein product of the SOST gene and is known for its inhibitory effects on bone formation. The monoclonal antibody against sclerostin has been approved as a novel treatment method for osteoporosis. Oral health is one of the essential aspects of general human health. Hereditary bone dysplasia syndrome caused by sclerostin deficiency is often accompanied by some dental malformations, inspiring the therapeutic exploration of sclerostin in the oral and dental fields. Recent studies have found that sclerostin is expressed in several functional cell types in oral tissues, and the expression level of sclerostin is altered in pathological conditions. Sclerostin not only exerts similar negative outcomes on the formation of alveolar bone and bone-like tissues, including dentin and cementum, but also participates in the development of oral inflammatory diseases such as periodontitis, pulpitis, and peri-implantitis. This review aims to highlight related research progress of sclerostin in oral cavity, propose necessary further research in this field, and discuss its potential as a therapeutic target for dental indications and regenerative dentistry.
Literature
1.
Van Hul W, Balemans W, Van Hul E, Dikkers FG, Obee H, Stokroos RJ, et al. Van buchem disease (hyperostosis corticalis generalisata) maps to chromosome 17q12-q21. Am J Hum Genet. 1998;62(2):391–9.PubMedPubMedCentralCrossRef
2.
Balemans W, Van Den Ende J, Paes-Alves AF, Dikkers FG, Willems PJ, Vanhoenacker F, et al. Localization of the gene for sclerosteosis to the van buchem disease–gene region on chromosome 17q12–q21. Am J Hum Genet. 1999;64(6):1661–9.PubMedPubMedCentralCrossRef
3.
Li X, Ominsky MS, Niu Q, Sun N, Daugherty B, D’Agostin D, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008;23(6):860–9.PubMedCrossRef
4.
Sutherland MK, Geoghegan JC, Yu C, Turcott E, Skonier JE, Winkler DG, et al. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone. 2004;35(4):828–35.PubMedCrossRef
5.
6.
Sun M, Chen Z, Wu X, Yu Y, Wang L, Lu A, et al. The roles of sclerostin in immune system and the applications of aptamers in immune-related research. Front Immunol. 2021;12(164): 602330.PubMedPubMedCentralCrossRef
7.
8.
Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, et al. Bone dysplasia sclerosteosis results from loss of the sost gene product, a novel cystine knot–containing protein. Am J Hum Genet. 2001;68(3):577–89.PubMedPubMedCentralCrossRef
9.
Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (sost). Hum Mol Genet. 2001;10(5):537–44.PubMedCrossRef
10.
Kim CA, Honjo R, Bertola D, Albano L, Oliveira L, Jales S, et al. A known sost gene mutation causes sclerosteosis in a familial and an isolated case from brazilian origin. Genet Test. 2008;12(4):475–9.PubMedCrossRef
11.
Piters E, Culha C, Moester M, Van Bezooijen R, Adriaensen D, Mueller T, et al. First missense mutation in the sost gene causing sclerosteosis by loss of sclerostin function. Hum Mutat. 2010;31(7):E1526–43.PubMedCrossRef
12.
Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, et al. Identification of a 52 kb deletion downstream of the sost gene in patients with van buchem disease. J Med Genet. 2002;39(2):91–7.PubMedPubMedCentralCrossRef
13.
Staehling-Hampton K, Proll S, Paeper BW, Zhao L, Charmley P, Brown A, et al. A 52-kb deletion in the sost-meox1 intergenic region on 17q12-q21 is associated with van buchem disease in the dutch population. Am J Med Genet. 2002;110(2):144–52.PubMedCrossRef
14.
Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, et al. Sclerostin mediates bone response to mechanical unloading through antagonizing wnt/beta-catenin signaling. J Bone Miner Res. 2009;24(10):1651–61.PubMedCrossRef
15.
Robling A, Niziolek P, Baldridge L, Condon K, Allen M, Alam I, et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of sost/sclerostin. J Biol Chem. 2008;283(9):5866–75.PubMedCrossRef
16.
Silvestrini G, Ballanti P, Leopizzi M, Sebastiani M, Berni S, Di Vito M, et al. Effects of intermittent parathyroid hormone (pth) administration on sost mrna and protein in rat bone. J Mol Histol. 2007;38(4):261–9.PubMedCrossRef
17.
Genetos DC, Toupadakis CA, Raheja LF, Wong A, Papanicolaou SE, Fyhrie DP, et al. Hypoxia decreases sclerostin expression and increases wnt signaling in osteoblasts. J Cell Biochem. 2010;110(2):457–67.PubMedPubMedCentral
18.
Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, et al. Osteocyte control of bone formation via sclerostin, a novel bmp antagonist. Embo J. 2003;22(23):6267–76.PubMedPubMedCentralCrossRef
19.
van Bezooijen RL, Svensson JP, Eefting D, Visser A, van der Horst G, Karperien M, et al. Wnt but not bmp signaling is involved in the inhibitory action of sclerostin on bmp-stimulated bone formation. J Bone Miner Res. 2007;22(1):19–28.PubMedCrossRef
20.
van Bezooijen RL, Roelen BAJ, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical bmp antagonist. J Exp Med. 2004;199(6):805–14.PubMedPubMedCentralCrossRef
21.
Rhee Y, Allen MR, Condon K, Lezcano V, Ronda AC, Galli C, et al. Pth receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. J Bone Miner Res. 2011;26(5):1035–46.PubMedCrossRef
22.
Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, Miyake A, et al. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem. 2003;278(26):24113–7.PubMedCrossRef
23.
Semenov M, Tamai K, He X. Sost is a ligand for lrp5/lrp6 and a wnt signaling inhibitor. J Biol Chem. 2005;280(29):26770–5.PubMedCrossRef
24.
Lim K-E, Bullock WA, Horan DJ, Williams BO, Warman ML, Robling AG. Co-deletion of lrp5 and lrp6 in the skeleton severely diminishes bone gain from sclerostin antibody administration. Bone. 2021;143: 115708.PubMedCrossRef
25.
Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ. Sclerostin stimulates osteocyte support of osteoclast activity by a rankl-dependent pathway. PLoS ONE. 2011;6(10): e25900.PubMedPubMedCentralCrossRef
26.
Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, et al. A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab. 2018;103(9):3183–93.PubMedCrossRef
27.
McClung MR, Brown JP, Diez-Perez A, Resch H, Caminis J, Meisner P, et al. Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res. 2018;33(8):1397–406.PubMedCrossRef
28.
Nealy KL, Harris KB. Romosozumab: a novel injectable sclerostin inhibitor with anabolic and antiresorptive effects for osteoporosis. Ann Pharmacother. 2021;55(5):677–86.PubMedCrossRef
29.
Toscani D, Bolzoni M, Ferretti M, Palumbo C, Giuliani N. Role of osteocytes in myeloma bone disease: anti-sclerostin antibody as new therapeutic strategy. Front Immunol. 2018;9:2467.PubMedPubMedCentralCrossRef
30.
Stephen L, Hamersma H, Gardner J, Beighton P. Dental and oral manifestations of sclerosteosis. Int Dent J. 2001;51(4):287–90.PubMedCrossRef
31.
Balemans W, Cleiren E, Siebers U, Horst J, Van Hul W. A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the sost gene. Bone. 2005;36(6):943–7.PubMedCrossRef
32.
Balli U, Aydogdu A, Dede FO, Turer CC, Guven B. Gingival crevicular fluid levels of sclerostin, osteoprotegerin, and receptor activator of nuclear factor-κb ligand in periodontitis. J Periodontol. 2015;86(12):1396–404.PubMedCrossRef
33.
Chatzopoulos GS, Costalonga M, Mansky KC, Wolff LF. Wnt-5a and sost levels in gingival crevicular fluid depend on the inflammatory and osteoclastogenic activities of periodontal tissues. Medicina. 2021;57(8):788.PubMedPubMedCentralCrossRef
34.
Yakar N, Guncu GN, Akman AC, Pınar A, Karabulut E, Nohutcu RM. Evaluation of gingival crevicular fluid and peri-implant crevicular fluid levels of sclerostin, tweak, rankl and opg. Cytokine. 2019;113:433–9.PubMedCrossRef
35.
Isler SC, Soysal F, Akca G, Bakirarar B, Ozcan G, Unsal B. The effects of decontamination methods of dental implant surface on cytokine expression analysis in the reconstructive surgical treatment of peri-implantitis. Odontology. 2021;109(1):103–13.PubMedCrossRef
36.
37.
Napimoga MH, Nametala C, da Silva FL, Miranda TS, Bossonaro JP, Demasi APD, et al. Involvement of the wnt-β-catenin signalling antagonists, sclerostin and dickkopf-related protein 1, in chronic periodontitis. J Clin Periodontol. 2014;41(6):550–7.PubMedCrossRef
38.
Sankardas PA, Lavu V, Lakakula BV, Rao SR. Differential expression of periostin, sclerostin, receptor activator of nuclear factor-κb, and receptor activator of nuclear factor-κb ligand genes in severe chronic periodontitis. J Investig Clin Dent. 2019;10(1): e12369.PubMedCrossRef
39.
Jäger A, Götz W, Lossdörfer S, Rath-Deschner B. Localization of sost/sclerostin in cementocytes in vivo and in mineralizing periodontal ligament cells in vitro. J Periodontal Res. 2010;45(2):246–54.PubMedCrossRef
40.
Manokawinchoke J, Limjeerajarus N, Limjeerajarus C, Sastravaha P, Everts V, Pavasant P. Mechanical force-induced tgfb1 increases expression of sost/postn by hpdl cells. J Dent Res. 2015;94(7):983–9.PubMedCrossRef
41.
Ueda M, Goto T, Kuroishi KN, Gunjigake KK, Ikeda E, Kataoka S, et al. Asporin in compressed periodontal ligament cells inhibits bone formation. Arch Oral Biol. 2016;62:86–92.PubMedCrossRef
42.
Nishiyama Y, Matsumoto T, Lee J, Saitou T, Imamura T, Moriyama K, et al. Changes in the spatial distribution of sclerostin in the osteocytic lacuno-canalicular system in alveolar bone due to orthodontic forces, as detected on multimodal confocal fluorescence imaging analyses. Arch Oral Biol. 2015;60(1):45–54.PubMedCrossRef
43.
Kim J-H, Kim AR, Choi YH, Kim A, Sohn Y, Woo G-H, et al. Intermittent pth administration improves alveolar bone formation in type 1 diabetic rats with periodontitis. J Transl Med. 2018;16(1):70.PubMedPubMedCentralCrossRef
44.
45.
Naka T, Yokose S. Spatiotemporal expression of sclerostin in odontoblasts during embryonic mouse tooth morphogenesis. J Endod. 2011;37(3):340–5.PubMedCrossRef
46.
Odagaki N, Ishihara Y, Wang Z, Ei Hsu Hlaing E, Nakamura M, Hoshijima M, et al. Role of osteocyte-pdl crosstalk in tooth movement via sost/sclerostin. J Dent Res. 2018;97(12):1374–82.PubMedCrossRef
47.
Yadav S, Assefnia A, Gupta H, Vishwanath M, Kalajzic Z, Allareddy V, et al. The effect of low-frequency mechanical vibration on retention in an orthodontic relapse model. Eur J Orthodont. 2016;38(1):44–50.CrossRef
48.
Shu R, Bai D, Sheu T, He Y, Yang X, Xue C, et al. Sclerostin promotes bone remodeling in the process of tooth movement. PLoS ONE. 2017;12(1): e0167312.PubMedPubMedCentralCrossRef
49.
Liu M, Kurimoto P, Zhang J, Niu Q, Stolina M, Dechow P, et al. Sclerostin and dkk1 inhibition preserves and augments alveolar bone volume and architecture in rats with alveolar bone loss. J Dent Res. 2018;97(9):1031–8.PubMedCrossRef
50.
Kim J, Lee D, Woo G, Cha J, Bak E, Yoo Y. Osteocytic sclerostin expression in alveolar bone in rats with diabetes mellitus and ligature-induced periodontitis. J Periodontol. 2015;86(8):1005–11.PubMedCrossRef
51.
Kim J, Lee D, Cha J, Bak E, Yoo Y. Receptor activator of nuclear factor-κb ligand and sclerostin expression in osteocytes of alveolar bone in rats with ligature-induced periodontitis. J Periodontol. 2014;85(11):e370–8.PubMedCrossRef
52.
Liao C, Ou Y, Wu Y, Zhou Y, Liang S, Wang Y. Sclerostin inhibits odontogenic differentiation of human pulp-derived odontoblast-like cells under mechanical stress. J Cell Physiol. 2019;234(11):20779–89.PubMedCrossRef
53.
54.
Amri N, Djole S, Petit S, Babajko S, Coudert A, Castaneda B, et al. Distorted patterns of dentinogenesis and eruption in msx2 null mutants: involvement of sost/sclerostin. Am J Pathol. 2016;186(10):2577–87.PubMedCrossRef
55.
Liao C, Wang Y, Ou Y, Wu Y, Zhou Y, Liang S. Effects of sclerostin on lipopolysaccharide-induced inflammatory phenotype in human odontoblasts and dental pulp cells. Int J Biochem Cell Biol. 2019;117: 105628.PubMedCrossRef
56.
Collignon A, Amri N, Lesieur J, Sadoine J, Ribes S, Menashi S, et al. Sclerostin deficiency promotes reparative dentinogenesis. J Dent Res. 2017;96(7):815–21.PubMedCrossRef
57.
Janjić K, Samiei M, Moritz A, Agis H. The influence of pro-inflammatory factors on sclerostin and dickkopf-1 production in human dental pulp cells under hypoxic conditions. Front Bioeng Biotechnol. 2019;7:430.PubMedPubMedCentralCrossRef
58.
Almeida ABD, Santos EJLD, Abuna GF, Ribeiro CS, Casati MZ, Ruiz KGS, et al. Isolation and characterization of a human cementocyte-like cell line, hcy-23. Braz Oral Res. 2019;33:e058.PubMedCrossRef
59.
Lehnen SD, Götz W, Baxmann M, Jäger A. Immunohistochemical evidence for sclerostin during cementogenesis in mice. Ann Anat. 2012;194(5):415–21.PubMedCrossRef
60.
Zhao N, Nociti FH, Duan P, Prideaux M, Zhao H, Foster BL, et al. Isolation and functional analysis of an immortalized murine cementocyte cell line, idg-cm6. J Bone Miner Res. 2016;31(2):430–42.PubMedCrossRef
61.
Klein-Nulend J, Bacabac R, Bakker A. Mechanical loading and how it affects bone cells: the role of the osteocyte cytoskeleton in maintaining our skeleton. Eur Cell Mater. 2012;24(2):279–91.
62.
63.
Klein-Nulend J, Bakker AD, Bacabac RG, Vatsa A, Weinbaum S. Mechanosensation and transduction in osteocytes. Bone. 2013;54(2):182–90.PubMedCrossRef
64.
Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, et al. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocr Metab. 2010;95(5):2248–53.PubMedCrossRef
65.
Kuchler U, Schwarze UY, Dobsak T, Heimel P, Bosshardt DD, Kneissel M, et al. Dental and periodontal phenotype in sclerostin knockout mice. Int J Oral Sci. 2014;6(2):70–6.PubMedPubMedCentralCrossRef
66.
Yao Y, Kauffmann F, Maekawa S, Sarment LV, Sugai JV, Schmiedeler CA, et al. Sclerostin antibody stimulates periodontal regeneration in large alveolar bone defects. Sci Rep. 2020;10(1):16217.PubMedPubMedCentralCrossRef
67.
68.
Tan WL, Wong TL, Wong MC, Lang NP. A systematic review of post-extractional alveolar hard and soft tissue dimensional changes in humans. Clin Oral Implan Res. 2012;23(Suppl 5):1–21.CrossRef
69.
Kitaura H, Kimura K, Ishida M, Sugisawa H, Kohara H, Yoshimatsu M, et al. Effect of cytokines on osteoclast formation and bone resorption during mechanical force loading of the periodontal membrane. Sci World J. 2014;2014: 617032.CrossRef
70.
Seo B, Miura M, Gronthos S, Bartold P, Batouli S, Brahim J, et al. Investigation of multipotent postnatal stem cells from human periodontal ligament. Lancet. 2004;364(9429):149–55.PubMedCrossRef
71.
Liu M, Dai J, Lin Y, Yang L, Dong H, Li Y, et al. Effect of the cyclic stretch on the expression of osteogenesis genes in human periodontal ligament cells. Gene. 2012;491(2):187–93.PubMedCrossRef
72.
Ren D, Wei F, Hu L, Yang S, Wang C, Yuan X. Phosphorylation of runx2, induced by cyclic mechanical tension via erk1/2 pathway, contributes to osteodifferentiation of human periodontal ligament fibroblasts. J Cell Physiol. 2015;230(10):2426–36.PubMedCrossRef
73.
Tang N, Zhao Z, Zhang L, Yu Q, Li J, Xu Z, et al. Up-regulated osteogenic transcription factors during early response of human periodontal ligament stem cells to cyclic tensile strain. Arch Med Sci. 2012;8(3):422–30.PubMedPubMedCentralCrossRef
74.
Zhao Y, Wang C, Li S, Song H, Wei F, Pan K, et al. Expression of osterix in mechanical stress-induced osteogenic differentiation of periodontal ligament cells in vitro. Eur J Oral Sci. 2008;116(3):199–206.PubMedCrossRef
75.
Ei Hsu Hlaing E, Ishihara Y, Odagaki N, Wang Z, Ikegame M, Kamioka H. The expression and regulation of wnt1 in tooth movement-initiated mechanotransduction. Am J Orthod Dentofacial Orthop. 2020;158(6):e151-60.PubMedCrossRef
76.
Lundgren T, Linde A. Voltage-gated calcium channels and nonvoltage-gated calcium uptake pathways in the rat incisor odontoblast plasma membrane. Calcif Tissue Int. 1997;60(1):79–85.PubMedCrossRef
77.
Lundquist P. Odontoblast phosphate and calcium transport in dentinogenesis. Swed Dent J Suppl. 2002;154:1–52.
78.
Liu Q, Ma N, Zhu Q, Duan X, Shi H, Xiang D, et al. Dentin sialophosphoprotein deletion leads to femoral head cartilage attenuation and subchondral bone ill-mineralization. J Histochem Cytochem. 2020;68(10):703–18.PubMedPubMedCentralCrossRef
79.
Magloire H, Romeas A, Melin M, Couble M, Bleicher F, Farges J. Molecular regulation of odontoblast activity under dentin injury. Adv Dent Res. 2001;15(1):46–50.PubMedCrossRef
80.
Mitsiadis T, Rahiotis C. Parallels between tooth development and repair: conserved molecular mechanisms following carious and dental injury. J Dent Res. 2004;83(12):896–902.PubMedCrossRef
81.
82.
Yagi T, Suga S. Sem investigations on the human sclerosed dentinal tubules. Shigaku. 1990;78(2):313–37.PubMed
83.
Bartlett D, Shah P. A critical review of non-carious cervical (wear) lesions and the role of abfraction, erosion, and abrasion. J Dent Res. 2006;85(4):306–12.PubMedCrossRef
84.
Bergstrom J, Eliasson S. Cervical abrasion in relation to toothbrushing and periodontal health. Scand J Dent Res. 1988;96(5):405–11.PubMed
85.
Tanaka M, Naito T, Yokota M, Kohno M. Finite element analysis of the possible mechanism of cervical lesion formation by occlusal force. J Oral Rehabil. 2003;30(1):60–7.PubMedCrossRef
86.
van Bezooijen R, Bronckers A, Gortzak R, Hogendoorn P, Van der Wee-Pals L, Balemans W, et al. Sclerostin in mineralized matrices and van buchem disease. J Dent Res. 2009;88(6):569–74.PubMedCrossRef
87.
Iglesias-Linares A, Hartsfield JK. Cellular and molecular pathways leading to external root resorption. J Dent Res. 2017;96(2):145–52.PubMedCrossRef
88.
Bao X, Liu Y, Han G, Zuo Z, Hu M. The effect on proliferation and differentiation of cementoblast by using sclerostin as inhibitor. Int J Mol Sci. 2013;14(10):21140–52.PubMedPubMedCentralCrossRef
89.
Bao X, Liu X, Zhang Y, Cui Y, Yao J, Hu M. Strontium promotes cementoblasts differentiation through inhibiting sclerostin expression in vitro. Biomed Res Int. 2014;2014: 487535.PubMedPubMedCentral
90.
Wei T, Xie Y, Wen X, Zhao N, Shen G. Establishment of three-dimensional cementocyte differentiation scaffolds to study orthodontic root resorption. Exp Ther Med. 2020;20(4):3174–84.PubMedPubMedCentral
91.
Bai S, Chen Y, Dai H, Huang L. Effect of sclerostin on the functions and related mechanisms of cementoblasts under mechanical stress. Hua Xi Kou Qiang Yi Xue Za Zhi. 2019;37(2):162–7.PubMed
92.
Durand SH, Flacher V, Roméas A, Carrouel F, Colomb E, Vincent C, et al. Lipoteichoic acid increases tlr and functional chemokine expression while reducing dentin formation in in vitro differentiated human odontoblasts. J Immunol. 2006;176(5):2880–7.PubMedCrossRef
93.
Farges JC, Carrouel F, Keller JF, Baudouin C, Msika P, Bleicher F, et al. Cytokine production by human odontoblast-like cells upon toll-like receptor-2 engagement. Immunobiology. 2011;216(4):513–7.PubMedCrossRef
94.
Abdalla R, Mitchell RJ, Fang Ren Y. Non-carious cervical lesions imaged by focus variation microscopy. J Dent. 2017;63:14–20.PubMedCrossRef
95.
Téclès O, Laurent P, Zygouritsas S, Burger A, Camps J, Dejou J, et al. Activation of human dental pulp progenitor/stem cells in response to odontoblast injury. Arch Oral Biol. 2005;50(2):103–8.PubMedCrossRef
96.
Sloan A, Smith A. Stem cells and the dental pulp: Potential roles in dentine regeneration and repair. Oral Dis. 2007;13(2):151–7.PubMedCrossRef
97.
Chen X, Baum W, Dwyer D, Stock M, Schwabe K, Ke H, et al. Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis. Ann Rheum Dis. 2013;72(10):1732–6.PubMedCrossRef
98.
Eddleston A, Marenzana M, Moore AR, Stephens P, Muzylak M, Marshall D, et al. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res. 2009;24(10):1662–71.PubMedCrossRef
99.
Marenzana M, Vugler A, Moore A, Robinson M. Effect of sclerostin-neutralising antibody on periarticular and systemic bone in a murine model of rheumatoid arthritis: a microct study. Arthritis Res Ther. 2013;15(5):R125.PubMedPubMedCentralCrossRef
100.
Feng X, Feng G, Xing J, Shen B, Tan W, Huang D, et al. Repeated lipopolysaccharide stimulation promotes cellular senescence in human dental pulp stem cells (dpscs). Cell Tissue Res. 2014;356(2):369–80.PubMedCrossRef
101.
102.
Iezzi I, Pagella P, Mattioli-Belmonte M, Mitsiadis TA. The effects of ageing on dental pulp stem cells, the tooth longevity elixir. Eur Cell Mater. 2019;37:175–85.PubMedCrossRef
103.
104.
Mödder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2011;26(2):373–9.PubMedCrossRef
105.
Roforth MM, Fujita K, McGregor UI, Kirmani S, McCready LK, Peterson JM, et al. Effects of age on bone mrna levels of sclerostin and other genes relevant to bone metabolism in humans. Bone. 2014;59:1–6.PubMedCrossRef
106.
Wehmeyer C, Frank S, Beckmann D, Böttcher M, Cromme C, König U, et al. Sclerostin inhibition promotes tnf-dependent inflammatory joint destruction. Sci Transl Med. 2016;8(330):330ra35.PubMedCrossRef
107.
108.
Korah L, Amri N, Bugueno IM, Hotton D, Tenenbaum H, Huck O, et al. Experimental periodontitis in msx2 mutant mice induces alveolar bone necrosis. J Periodontol. 2020;91(5):693–704.PubMedCrossRef
109.
Taut AD, Jin Q, Chung J, Galindo-Moreno P, Yi ES, Sugai JV, et al. Sclerostin antibody stimulates bone regeneration after experimental periodontitis. J Bone Miner Res. 2013;28(11):2347–56.PubMedCrossRef
110.
Balli U, Keles ZP, Avci B, Guler S, Cetinkaya BO, Keles GC. Assessment of periostin levels in serum and gingival crevicular fluid of patients with periodontal disease. J Periodontal Res. 2015;50(6):707–13.PubMedCrossRef
111.
Aral CA, Köseoğlu S, Sağlam M, Pekbağrıyanık T, Savran L. Gingival crevicular fluid and salivary periostin levels in non-smoker subjects with chronic and aggressive periodontitis : periostin levels in chronic and aggressive periodontitis. Inflammation. 2016;39(3):986–93.PubMed
112.
Ríos HF, Ma D, Xie Y, Giannobile WV, Bonewald L, Conway S, et al. Periostin is essential for the integrity and function of the periodontal ligament during occlusal loading in mice. J Periodontol. 2008;79(8):1480–90.PubMedPubMedCentralCrossRef
113.
Ren Y, Han X, Ho SP, Harris SE, Cao Z, Economides AN, et al. Removal of sost or blocking its product sclerostin rescues defects in the periodontitis mouse model. Faseb J. 2015;29(7):2702–11.PubMedPubMedCentralCrossRef
114.
Virdi AS, Liu M, Sena K, Maletich J, McNulty M, Ke HZ, et al. Sclerostin antibody increases bone volume and enhances implant fixation in a rat model. J Bone Joint Surg Am. 2012;94(18):1670–80.PubMedPubMedCentralCrossRef
115.
Liu S, Virdi AS, Sena K, Sumner DR. Sclerostin antibody prevents particle-induced implant loosening by stimulating bone formation and inhibiting bone resorption in a rat model. Arthritis Rheum. 2012;64(12):4012–20.PubMedCrossRef
116.
Yu SH, Hao J, Fretwurst T, Liu M, Kostenuik P, Giannobile WV, et al. Sclerostin-neutralizing antibody enhances bone regeneration around oral implants. Tissue Eng Part A. 2018;24(21–22):1672–9.PubMedPubMedCentralCrossRef
117.
Maillard S, Sicard L, Andrique C, Torrens C, Lesieur J, Baroukh B, et al. Combining sclerostin neutralization with tissue engineering: an improved strategy for craniofacial bone repair. Acta Biomater. 2022;140:178–89.PubMedCrossRef
118.
Hu B, Li Y, Wang M, Zhu Y, Zhou Y, Sui B, et al. Functional reconstruction of critical-sized load-bearing bone defects using a sclerostin-targeting mir-210-3p-based construct to enhance osteogenic activity. Acta Biomater. 2018;76:275–82.PubMedCrossRef
119.
Shu R, Ai D, Bai D, Song J, Zhao M, Han X. The effects of sost on implant osseointegration in ovariectomy osteoporotic mice. Arch Oral Biol. 2017;74:82–91.PubMedCrossRef
120.
Korn P, Kramer I, Schlottig F, Tödtmann N, Eckelt U, Bürki A, et al. Systemic sclerostin antibody treatment increases osseointegration and biomechanical competence of zoledronic-acid-coated dental implants in a rat osteoporosis model. Eur Cell Mater. 2019;37:333–46.PubMedCrossRef
121.
Chen X, Moriyama Y, Takemura Y, Rokuta M, Ayukawa Y. Influence of osteoporosis and mechanical loading on bone around osseointegrated dental implants: a rodent study. J Mech Behav Biomed Mater. 2021;123: 104771.PubMedCrossRef
122.
Fixen C, Tunoa J. Romosozumab: a review of efficacy, safety, and cardiovascular risk. Curr Osteoporos Rep. 2021;19(1):15–22.PubMedCrossRef
123.
Singh S, Dutta S, Khasbage S, Kumar T, Sachin J, Sharma J, et al. A systematic review and meta-analysis of efficacy and safety of romosozumab in postmenopausal osteoporosis. Osteoporos Int. 2022;33(1):1–12.PubMedCrossRef
124.
125.
Brandenburg VM, Verhulst A, Babler A, D’Haese PC, Evenepoel P, Kaesler N. Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it! Nephrol Dial Transplant. 2019;34(3):408–14.PubMedCrossRef
Metadata
Title
Sclerostin is a promising therapeutic target for oral inflammation and regenerative dentistry
Authors
Chufang Liao
Shanshan Liang
Yining Wang
Ting Zhong
Xiangning Liu
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-022-03417-4

Other articles of this Issue 1/2022

Journal of Translational Medicine 1/2022 Go to the issue

Meeting report

The future of cancer immunotherapy for brain tumors: a collaborative workshop

Research

CAFs-derived SCUBE1 promotes malignancy and stemness through the Shh/Gli1 pathway in hepatocellular carcinoma

Research

Melatonin increases bone mass in normal, perimenopausal, and postmenopausal osteoporotic rats via the promotion of osteogenesis

Research

Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML)

Research

Multi-scale pathology image texture signature is a prognostic factor for resectable lung adenocarcinoma: a multi-center, retrospective study

Research

MAL protein suppresses the metastasis and invasion of GC cells by interfering with the phosphorylation of STAT3
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits